These limitations also reveal a strength of our studies — namely, the systemic administration of a pharmacologic agent (HC-5770), which provides context for how PERK inhibition might be leveraged in humans for the prevention/delay of T1D. The gene discussed is EIF2AK3; the disease is type 1 diabetes mellitus.